| |
| Device | COBAS CMV |
| Generic Name | Cytomegalovirus (cmv) dna quantitative assay |
| Regulation Number | 866.3180 |
| Applicant | Roche Molecular Systems, Inc. 4300 Hacienda Dr. Pleasanton, CA 94588 |
| PMA Number | P160041 |
| Date Received | 09/21/2016 |
| Decision Date | 06/01/2017 |
| Reclassified Date | 10/23/2024 |
| Product Code |
PAB |
| Docket Number | 17M-3430 |
| Notice Date | 06/07/2017 |
| Advisory Committee |
Microbiology |
| Expedited Review Granted? | No |
| Combination Product | No |
| Predetermined Change Control Plan Authorized | No |
Approval Order Statement Approval of the cobas CMV test - This device is indicated for:cobas® CMV is an in vitro nucleic acid amplification test for the quantitation of cytomegalovirus (CMV) DNA in human EDTA plasma. cobas® CMV is intended for use as an aid in the management of CMV in solid organ transplant patients and in hematopoietic stem cell transplant patients. In patients receiving anti-CMV therapy, serial DNA measurements can be used to assess viral response to treatment. The results from cobas® CMV must be interpreted within the context of all relevant clinical and laboratory findings. cobas® CMV is not intended for use as a screening test for blood or blood products. |
| Approval Order | Approval Order |
| Summary | Summary of Safety and Effectiveness |
| Labeling | Labeling
|
| Supplements: |
S001 S009 S010 S011 S005 S002 S003 S018 S019 S020 S021 S022 S025 S026 S014 S015 S028 S033 S034 S036 S008 S004 S012 S013 S006 S007 S023 S030 S029 S031 S027 S024 S017 S016 S032 S035 S037 S038 S039 S040 S041 S045 S046 S042 S043 S044 |